全文获取类型
收费全文 | 907篇 |
免费 | 62篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 40篇 |
妇产科学 | 6篇 |
基础医学 | 128篇 |
口腔科学 | 8篇 |
临床医学 | 113篇 |
内科学 | 223篇 |
皮肤病学 | 4篇 |
神经病学 | 31篇 |
特种医学 | 177篇 |
外科学 | 89篇 |
综合类 | 12篇 |
预防医学 | 47篇 |
眼科学 | 8篇 |
药学 | 43篇 |
肿瘤学 | 61篇 |
出版年
2022年 | 2篇 |
2021年 | 7篇 |
2020年 | 11篇 |
2019年 | 11篇 |
2018年 | 18篇 |
2017年 | 8篇 |
2016年 | 14篇 |
2015年 | 19篇 |
2014年 | 26篇 |
2013年 | 33篇 |
2012年 | 29篇 |
2011年 | 30篇 |
2010年 | 21篇 |
2009年 | 23篇 |
2008年 | 29篇 |
2007年 | 32篇 |
2006年 | 26篇 |
2005年 | 38篇 |
2004年 | 24篇 |
2003年 | 23篇 |
2002年 | 25篇 |
2001年 | 25篇 |
2000年 | 23篇 |
1999年 | 25篇 |
1998年 | 32篇 |
1997年 | 31篇 |
1996年 | 43篇 |
1995年 | 31篇 |
1994年 | 20篇 |
1993年 | 28篇 |
1992年 | 18篇 |
1991年 | 13篇 |
1990年 | 17篇 |
1989年 | 27篇 |
1988年 | 28篇 |
1987年 | 31篇 |
1986年 | 17篇 |
1985年 | 24篇 |
1984年 | 12篇 |
1983年 | 10篇 |
1982年 | 20篇 |
1981年 | 10篇 |
1980年 | 11篇 |
1979年 | 6篇 |
1978年 | 3篇 |
1977年 | 9篇 |
1976年 | 18篇 |
1975年 | 7篇 |
1971年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有991条查询结果,搜索用时 15 毫秒
31.
Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia 总被引:1,自引:0,他引:1
Koldehoff M Beelen DW Trenschel R Steckel NK Peceny R Ditschkowski M Ottinger H Elmaagacli AH 《Bone marrow transplantation》2004,34(12):1047-1050
Atypical chronic myeloid leukemia (aCML) occurs rarely and is associated with a poor prognosis when treated with conventional chemotherapy. We evaluated the outcome of aCML after allogeneic hematopoietic stem cell transplantation (HSCT). Nine patients were transplanted from HLA-identical siblings (n = 4), HLA-compatible unrelated donors (n = 4) or twin brother (n = 1). Median follow-up was 55 months after transplant (range, 9.1-118.1 months). One patient who was transplanted in advanced disease with bone marrow from his twin brother relapsed 19 months post transplant. This patient was successfully retransplanted from the original donor. All patients remained in complete remission. Analysis of the leukocyte chimerism of peripheral white blood cells and bone marrow buffy coat cells by VNTR-polymerase chain reaction (PCR) and single-nucleotide polymorphism real-time PCR revealed complete chimerism in all patients who had received an allogeneic transplant. One patient suffering from cerebral toxoplasmosis died 9 months post transplant. All other patients were alive at the time of analysis. Our findings suggest that the outcome of allogeneic or syngeneic transplantation in patients with aCML may not be worse than the outcome of transplantation for BCR-ABL-positive CML. 相似文献
32.
The combination of high-dose busulfan (16 mg/kg) and 200 mg/kg cyclophosphamide is gaining increasing significance as a preparative regimen prior to autologous, syngeneic, or allogeneic marrow transplantation. A new regimen of high-dose busulfan in conjunction with a reduced dose of 120 mg/kg cyclophosphamide has recently been described as a preparative regimen prior to allogeneic transplantation. To determine the drug-related nonhematologic toxic effects of this new regimen without confounding factors associated with allogeneic transplantation, we conducted a pilot study using this new regimen in 20 patients with acute myeloid leukemia (AML) in first remission prior to autologous unpurged marrow transplantation. All patients experienced transient non-life-threatening acute drug-related toxicity with skin reactions in 20 (100%), nausea and vomiting in 20 (100%), oral mucositis in 18 (90%), hepatic functional impairment in 17 (85%), hemorrhagic cystitis in three (15%), and generalized seizures in two (10%) of these patients, respectively. Two procedural, fatal complications resulted from infectious causes that were not directly related to the speed of hematopoietic reconstitution or the toxicity of the preparative regimen. The 3-year event-free survival estimate (55% +/- 11%) and probability of leukemic recurrence (38% +/- 11%) attained with this new regimen in recipients of autografts in first remission of AML are promising and challenge comparisons with preparative regimens employing combinations of cytotoxic agents or total body irradiation (TBI). 相似文献
33.
An antibody (DIL) from a patient with idiopathic thrombocytopenic purpura (ITP) was shown to have autospecificity on the basis of reactions with autologous platelets that were identical to those obtained with platelets from normal subjects. DIL antibody also reacted strongly in an immunofluorescence test with platelets from a patient with Glanzmann's thrombasthenia, but failed to react with platelets from a patient with the Bernard-Soulier syndrome who was known to be deficient in glycoprotein Ib (GPIb). Purified GPIb and control platelets, but not Bernard-Soulier platelets, inhibited the lytic activity of DIL. Using the GPIb-specific monoclonal antibody AP1 and one-dimensional rocket electrophoresis into gels containing rabbit antihuman platelet membrane antibody, it was shown that staphylococcal protein A-Sepharose beads coated with DIL antibody selectively remove GPIb from solubilized platelet preparations. By crossed immunoelectrophoresis it was found that DIL recognizes a determinant on GPIb on the membrane side of the cleavage site of the platelet calcium- activated protease (calpain). These studies provide direct evidence for binding of a platelet autoantibody to a determinant on GPIb relatively close to the site of insertion of this protein into the platelet membrane. 相似文献
34.
35.
Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T‐cell cross‐priming
下载免费PDF全文
![点击此处可从《European journal of immunology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Cynthia M. Fehres Sven C. M. Bruijns Astrid J. van Beelen Hakan Kalay Martino Ambrosini Erik Hooijberg Wendy W. J. Unger Tanja D. de Gruijl Yvette van Kooyk 《European journal of immunology》2014,44(8):2415-2424
Toll‐like receptor (TLR) ligands are attractive candidate adjuvants for therapeutic cancer vaccines, since TLR signaling stimulates and tunes both humoral and cellular immune responses induced by dendritic cells (DCs). Given that human skin contains a dense network of DCs, which are easily accessible via (intra‐)dermal delivery of vaccines, skin is actively explored as an antitumor vaccination site. Here we used a human skin explant model to explore the potential of TLR ligands as adjuvants for DC activation in their complex microenvironment. We show that topical application of Aldara skin cream, 5% of which comprises the TLR7 agonist imiquimod, significantly enhanced DC migration as compared with that resulting from intradermal injection of the TLR7/8 ligand R848 or the soluble form of imiquimod. Moreover, Aldara‐treated DCs showed highest levels of the costimulatory molecules CD86, CD83, CD40, and CD70. Topical Aldara induced the highest production of pro‐inflammatory cytokines in skin biopsies. When combined with intradermal peptide vaccination, Aldara‐stimulated DCs showed enhanced cross‐presentation of the melanoma antigen MART‐1, which resulted in increased priming and activation of MART‐1‐specific CD8+ T cells. These results point to advantageous effects of combining the topical application of Aldara with antitumor peptide vaccination. 相似文献
36.
37.
38.
Helleman Jochem Bakers Jaap N. E. Pirard Evelien van den Berg Leonard H. Visser-Meily Johanna M. A. Beelen Anita 《Journal of neurology》2022,269(7):3713-3722
Journal of Neurology - Home-monitoring of spirometry has the potential to improve care for patients with a motor neuron disease (MND) by enabling early detection of respiratory dysfunction and... 相似文献
39.
40.
Natural killer (NK)–cell alloreactivity can be exploited in haploidentical hematopoietic stem cell transplantation (HSCT). NK cells from donors whose HLA type includes Bw4, a public epitope present on a subset of HLA-B alleles, can be alloreactive toward recipients whose cells lack Bw4. Serologically detectable epitopes related to Bw4 also exist on a subset of HLA-A alleles, but the interaction of these alleles with KIR3DL1 is controversial. We therefore undertook a systematic analysis of the ability of most common HLA-B alleles and HLA-A alleles with Bw4 serologic reactivity to protect target cells from lysis by KIR3DL1-dependent NK cells. All Bw4– HLA-B alleles failed to protect target cells from lysis. All Bw4+ HLA-B alleles with the exception of HLA-B*1301 and -B*1302 protected targets from lysis. HLA-A*2402 and HLA-A*3201 unequivocally protected target cells from lysis, whereas HLA-A*2501 and HLA-A*2301 provided only weak protection from lysis. KIR3DL1-dependent alloreactive NK clones were identified in donors with HLA-A*2402 but not in donors with HLA-B*1301 or -B*1302. These findings clarify the HLA types that donors and recipients need in haploidentical HSCT and other NK allotherapies in order to benefit from NK alloreactivity. 相似文献